Trial reportDiabetes care2018
Improved Health-Related Quality of Life in a Phase 3 Islet Transplantation Trial in Type 1 Diabetes Complicated by Severe Hypoglycemia.
Trial report in Diabetes care, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 58 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
58 citing papers in PubMed, 118 citations in OpenAlex.
- Phase 3 trial of human islet-after-kidney transplantation in type 1 diabetes.American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons · 2021Trial
- Advancing Type 1 Diabetes Treatment: 3 PM-Oriented Innovations in Islet Transplantation and Biomaterial Engineering.Diabetes/metabolism research and reviews · 2026Review
- Pancreatic Islet Transplantation in Extrahepatic Sites: Evaluation of the Venous Sac in Large Mammal Models.Diabetes & metabolism journal · 2026Article
- Donation After Circulatory Death Islets are Comparable to Standard-of-Care Donation After Brain Death Islets: Analysis of 801 Consecutive Human Islet Isolations.Transplantation direct · 2026Article
- Engineering Stem Cells for Islet Replacement Therapy: Recent Advances and Barriers for Clinical Translation.Cells · 2026Review
- Adults with type 1 diabetes define what matters to them in stem-cell derived islet cell therapy.Nature medicine · 2026Article
- CCL22-expressing Stem Cell-derived Islet Grafts Recruit Regulatory T Cells in Mice.Transplantation · 2026Article
- Article
- Concept analysis of diabetes-related quality of life.Health and quality of life outcomes · 2025Review
- Efficacy and Safety of Allogeneic Islet Transplantation Demonstrated by a Multicenter Clinical Trial in Japan.Transplantation direct · 2025Article
- Immunometabolic reprogramming in diabetic osteomyelitis: from mechanisms to therapeutics.Frontiers in cellular and infection microbiology · 2025Review
- From Edmonton to Lantidra and beyond: immunoengineering islet transplantation to cure type 1 diabetes.Frontiers in transplantation · 2025Review
- The bio-artificial pancreas to treat type 1 diabetes: Perspectives from healthcare professionals in the Netherlands.Journal of clinical & translational endocrinology · 2024Article
- Alternative therapeutic strategies in diabetes management.World journal of diabetes · 2024Review
- Biological hypoxia in pre-transplant human pancreatic islets induces transplant failure in diabetic mice.Scientific reports · 2024Article
- Drug Integrating Amphiphilic Nano-Assemblies: 2. Spatiotemporal Distribution within Inflammation Sites.Pharmaceutics · 2024Article
- Article
- Identifying Promising Immunomodulators for Type 1 Diabetes (T1D) and Islet Transplantation.Journal of diabetes research · 2024Review
- Combinatorial islet protective therapeutic approaches in β-cell transplantation: Rationally designed solutions using a target product profile.FASEB bioAdvances · 2023Review
- Validation of Igls Criteria for Islet Transplant Functional Status Using Person-Reported Outcome Measures in a Cross-Sectional Study.Transplant international : official journal of the European Society for Organ Transplantation · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 4 institutions in 1 country.
Funding
Abstract
objectiveAttaining glycemic targets without severe hypoglycemic events (SHEs) is a challenging treatment goal for patients with type 1 diabetes complicated by impaired awareness of hypoglycemia (IAH). The CIT Consortium Protocol 07 (CIT-07) trial showed islet transplantation to be an effective treatment for subjects with IAH and intractable SHEs. We evaluated health-related quality of life (HRQOL), functional health status, and health utility before and after pancreatic islet transplantation in CIT-07 trial participants. RESEARCH DESIGN AND
methodsFour surveys, the Diabetes Distress Scale (DDS), the Hypoglycemic Fear Survey (HFS), the Short Form 36 Health Survey (SF-36), and the EuroQoL 5 Dimensions (EQ-5D), were administered repeatedly before and after islet transplantation. Summary statistics and longitudinal modeling were used to describe changes in survey scores from baseline and to characterize change in relation to a minimally important difference (MID) threshold of half an SD.
resultsImprovements in condition-specific HRQOL met the MID threshold. Reductions from baseline in the DDS total score and its four DDS subscales (all
conclusionsIn CIT-07, 87.5% of the subjects achieved the primary end point of freedom from SHE along with glycemic control (HbA
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.